Rob Stein

The Biden administration is scrapping plans to offer COVID boosters for people under 50 this summer. Instead officials will push for an earlier release of the next generation boosters in the fall.

Evusheld, a course of injected antibodies, helps protect people with weak immune systems for up to six months. The government is making it available through pharmacies and individual providers.

The Biden administration may scrap plans to expand eligibility for second boosters to younger adults. Instead, it's trying to speed up the next generation of boosters targeting the omicron variant.

President Biden's COVID infection underscores a new surge of the pandemic, with another highly contagious virus strain and a federal scramble to provide more boosters to try to protect people.

The Biden administration is considering expanding eligibility for a second COVID-19 booster to those under 50 to try to protect more people against the latest omicron surge.

Dr. Anthony Fauci says he will step down before the end of President Biden's first term, but he has not chosen an exact date and is not sure what he will do after he leaves his position.

COVID vaccine makers are developing new boosters for a fall campaign. But some experts question the FDA's decision to tell companies to make shots against the BA.4/5 subvariants.

With COVID vaccines rolling out for younger children, NPR health correspondent Rob Stein and pediatrician Dr. Nia Heard-Garris are answering listener questions.

FDA advisers recommended the agency authorize new COVID-19 vaccines targeted at omicron to protect people against what could be another winter surge.

The Food and Drug Administration is meeting on Tuesday to make an extremely difficult but important decision: Should vaccines be updated to target the omicron variant?

Centers for Disease Control and Prevention Director Rochelle Walensky has cleared the way for the roll out of vaccines for children five years and under as early as this coming week.

Some scientists estimate that cases of long COVID from omicron will still rise, however, because of high transmissibility and the misconception that people don't have to worry about catching it.

Food and Drug Administration advisers are opening a two-day meeting to review Moderna and Pfizer-BioNTech's COVID-19 vaccines for children, including the first vaccines for kids younger than age 5.

Food and Drug Administration has released Moderna's data supporting the company's claim that its pediatric vaccines appear to be safe and effective, including for children as young as six months old.

Moderna says a new version of the company's COVID-19 vaccine appears to be highly effective against the omicron variant.

Moderna saysa new version of its COVID-19 vaccine appears to provide strong protection against the omicron variant as well as the original viral strain.

The "bivalent" vaccine — meaning it targets two different antigens — is Moderna's leading candidate for an effective booster this fall. If the data pan out, it could lead to a yearly booster.

The Food and Drug Administration advisory committee recommends the agency authorize another COVID-19 vaccine in the hopes it might entice more people to get vaccinated.

Advisers to the Food and Drug Administration overwhelmingly voted to recommend that it authorize Novavax's two-dose vaccine against COVID-19.

FDA scientists say another COVID-19 vaccine appears to be highly effective, potentially offering a new tool to entice the millions of people who still aren't vaccinated to finally get inoculated.